The financing was led by investments from two venture capital funds: Quaker BioVentures and SR One, the venture capital arm of GlaxoSmithKline.
Previous investors, Safeguard Scientifics, Bay City Capital/Birchmere Ventures, Battelle Ventures and BioAdvance Ventures participated in the round. Michael Diem, principal at SR One will join NuPathe’s board of directors.
Jane Hollingsworth, CEO and co-founder of NuPathe, said: “NuPathe is now in a position to optimize the development and commercialization of NP101, a unique treatment for acute migraine, as well as NP201, a novel product for Parkinson’s disease.”